QuadraMed Corporation (NASDAQ:QDHC) announced today that it will
report net income of $1.8 million before preferred stock accretion
for the three months ended June 30, 2008, compared to $2.2 million
for the same period in 2007. For the six months ended June 30,
2008, the Company had net income before preferred stock accretion
of $2.1 million, compared to $4.8 million for the six months ended
June 30, 2007. The Company began recording deferred income tax
expense at its statutory effective tax rate during the fourth
quarter of 2007; therefore, where there was deferred income tax
expense included in these reported 2008 results, there was no
comparable deferred income tax expense in the corresponding 2007
periods. Income before income taxes was $2.9 million for the three
months ended June 30, 2008, compared to $2.4 million for the same
period in 2007. For the six months ended June 30, 2008, the Company
had income before income taxes of $3.4 million, compared to $5.1
million for the six months ended June 30, 2007. In addition,
included in the three month and six month periods ended June 30,
2008 was a $1.1 million loss on the sale of the Company�s
Australia-based lab and radiology assets, as well as severance
costs of $0.2 million and $0.7 million in the periods,
respectively. No amounts of this nature were recorded in the
corresponding 2007 periods. The Company recorded revenue of $38.0
million for the quarter ended June 30, 2008, compared to $34.4
million for the same period last year, an increase of 10.5%. For
the six months ended June 30, 2008, revenue increased 15.3% to
$73.3 million, from $63.6 million for the comparable 2007 period.
The majority of the increase in revenue between periods was
attributable to the addition of the acquired QCPR product to the
Company�s portfolio, resulting from the integration of the
Computerized Patient Record (CPR) business assets during the fourth
quarter of 2007. As previously announced at the UBS Global
Healthcare Conference in February, and in its May 9, 2008 press
release, QuadraMed expects 2008 revenue to be between $146 million
and $152 million, which would represent a 6% to 10% increase over
2007 revenue of $137.4 million. Sales bookings for the first two
quarters of 2008 reached $33.5 million, a 36% increase over the
same period in 2007. Reflecting the strength of the Company's broad
product portfolio and brand appeal, several large hospital systems
selected QuadraMed's enterprise health solutions during the period
to enhance their quality of care and improve financial performance,
including an $8.8 million sales contract with Saudi Arabia National
Guard Health Affairs, located in Riyadh, Saudi Arabia, for QCPR
service expansion, migration to InterSystem�s Cache database and
interface licenses. In addition, on August 1, 2008, Daughters of
Charity Health System of Los Altos Hills, California signed a $15.8
million contract for the Phase II and Phase III options of a Master
Agreement that was originally finalized on November 30, 2006, prior
to QuadraMed�s acquisition of the QCPR business. Phase II and Phase
III include the purchase of software and services for the QCPR
platform including interactive care-grid, order management, access
management, clinical decision support, nursing documentation, chart
management and additional software for scheduling, electronic
document management, medical records, computerized physician order
entry and patient registration, all for their five facility network
of hospitals. The Phase I option, that was ordered at the same time
as the Master Agreement, included the purchase of software,
services and hardware for an integrated medication management
system, and was valued at $6.7 million. Income from operations was
$2.8 million and $1.3 million for the three month periods ended
June 30, 2008 and 2007, and $3.2 million and $3.5 million for the
six month periods ended June 30, 2008 and 2007, respectively.
Adjusted Non-GAAP EBITDA (Earnings Before Interest, Taxes,
Depreciation and Amortization, adjusted for stock based
compensation, severance and loss on the sale of assets) was $6.1
million for the three months ended June 30, 2008, compared to
adjusted Non-GAAP EBITDA of $3.4 million for the same period in
2007. For the six months ended June 30, 2008, the Company had
adjusted Non-GAAP EBITDA of $9.0 million, compared to $7.5 million
for the six months ended June 30, 2007. The increases in income
from operations and Non-GAAP adjusted EBITDA for the 2008 periods,
when compared to the corresponding 2007 periods, were due to the
stronger amounts of gross margin on revenues. The Company also
reported net income to common shareholders of $0.4 million, or
$0.05 income per basic share and $0.04 income per diluted share for
the three months ended June 30, 2008, and net loss to common
shareholders of $(0.7) million, or $(0.07) loss per basic and
diluted share for the six months ended June 30, 2008. This is
compared to a net income to common shareholders of $0.9 million, or
income per share of $0.10 basic and $0.09 diluted, and net income
to common shareholders of $2.2 million, or income per share of
$0.25 basic and $0.23 diluted for the corresponding periods in
2007. The primary reasons for the decline in earnings per share for
the 2008 periods were the aforementioned severance and loss on the
sale of assets, as well as the recording of deferred income tax
expense during 2008 at the Company�s effective rate, where there
was no such expense in the 2007 periods. Cash provided by operating
activities was $4.1 million for the quarter ended June 30, 2008,
compared to $4.9 million for the same period last year, and for the
six months ended June 30, 2008, cash provided by operating
activities was $12.1 million, compared to cash from operations of
$13.8 million for the comparable 2007 period. Overall, cash, cash
equivalents and investments increased to $23.2 million at June 30,
2008, from $22.1 million at March 31, 2008 and from $17.5 million
at December 31, 2007. This $5.7 million increase since year-end
occurred despite the Company�s use of $3.7 million to repurchase
its own common stock during the period. �Our results from the first
half of 2008 demonstrate our ability to produce revenue growth and
increased sales bookings while managing such operational challenges
as the QCPR acquisition integration and our divestiture of the
Australia-based lab and radiology assets. The QCPR acquisition,
especially in terms of sales bookings, is meeting my expectations,
and the cumulative total contract value of our signed QCPR
contracts now exceeds the $33 million we paid for that business
just 10 months ago. The recently announced SANG and Daughters of
Charity contracts are the largest non-government contracts
QuadraMed has signed since I became CEO in late 2005. I believe
this recent sales success is market validation of our strategy and
the QCPR acquisition decision, and further, that QCPR is viewed as
a competitive clinical information system for the hospital market,�
said Keith B. Hagen, QuadraMed�s President and Chief Executive
Officer. On June 16, 2008, QuadraMed announced the effectiveness of
a one-for-five reverse stock split that was approved by the
Company�s stockholders at the Company�s 2008 Annual Meeting of
Stockholders and the Company�s Board of Directors. The Company�s
common stock began trading on a split-adjusted basis on the
American Stock Exchange on June 16, 2008. On July 9, 2008, the
Company�s common stock began trading on the NASDAQ Global Market
under the symbol QDHC and was concurrently delisted from the
American Stock Exchange. Today, the Company also announced that
David L. Piazza, Chief Financial Officer, Executive Vice President,
Corporate Secretary and Treasurer, has provided notice of his
resignation, to be effective August 29, 2008. Mr. Piazza has served
as Chief Financial Officer since August 2005. Mr. Piazza has
accepted a position as chief operating officer of a private
software company in Northern Virginia. During the Company�s search
for Mr. Piazza�s permanent replacement, the Company has named Lora
Zalewski, Vice President of Finance, to serve as interim Chief
Financial Officer beginning on September 1, 2008. Ms. Zalewski
joined the Company in May 2004 as Director of Finance and was
promoted to Vice President of Finance in March 2006. Prior to
joining the Company, Ms. Zalewski served as Area Controller for
AT&T Government Solutions from October 2002 to May 2004. �Dave
Piazza has been a valuable part of our executive team for the past
three years. We are grateful for his contributions to the Company�s
strategic plan, especially in helping to reduce expenses and drive
revenue growth, and we wish him the best in his future endeavors,�
said Mr. Hagen. �My decision to leave the Company was not an easy
one. I have enjoyed serving as QuadraMed's CFO and working with
Keith to drive the Company to profitability and to strengthen its
internal controls and business processes. I have a tremendous
amount of respect for Keith and my colleagues on his senior
leadership team. The Company is well-positioned to continue its
growth and execution of its strategic goals,� said Mr. Piazza. �I
wish the Company continued success.� Management will review these
results in an investment community conference call at 5:00 PM
Eastern (2:00 PM Pacific) on Friday, August 8, 2008. To ensure fair
dissemination of information, no inquiries of management should be
made regarding QuadraMed�s results until after the conference call.
A brief question and answer period will follow management�s
presentation. The dial-in number for the conference call is
877-723-9521 domestic and 719-325-4814 international. Callers
should dial in by 4:45 PM Eastern (1:45 PM Pacific) to register.
The call will also be webcast live and is available to the public
via the Investor Relations section of QuadraMed�s webpage at
www.quadramed.com. Please note that the webcast is listen-only.
Listeners should access the website at 4:45 PM Eastern (1:45 PM
Pacific) to register and to download and install any necessary
audio software. The webcast replay will be available shortly after
the live call is completed and will be available until August 15,
2008. Replay telephone numbers are 719-457-0820 or 888-203-1112;
the replay passcode is 3302468. Attachments � Exhibit 1 � Condensed
Consolidated Balance Sheets (unaudited) as of June 30, 2008 and
December 31, 2007 Exhibit 2 Condensed Consolidated Statements of
Operations (unaudited) for the Three Months Ended June 30, 2008 and
2007 and the Six Months Ended June 30, 2008 and 2007 Exhibit 3
Condensed Consolidated Statements of Cash Flows (unaudited) for the
Three Months Ended June 30, 2008 and 2007 and the Six Months Ended
June 30, 2008 and 2007 Exhibit 4 Reconciliation of EBITDA and
Non-GAAP Measurements (unaudited) for the Three Months Ended June
30, 2008, March 31, 2008, December 31, 2007, September 30, 2007,
June 30, 2007, March 31, 2007, December 31, 2006, and September 30,
2006 Exhibit 5 Reconciliation of EBITDA and Non-GAAP Measurements
(unaudited) for the Six Months Ended June 30, 2008 and June 30,
2007 About Adjusted Non-GAAP EBITDA and other Non-GAAP Measurements
The Company�s use and presentation of the terms EBITDA, Adjusted
Non-GAAP EBITDA and other Non-GAAP Measurements included in this
press release and Exhibits 4 and 5 attached hereto, and the
reconciliations of those items to the most directly comparable GAAP
financial measure with equal or greater prominence as the Non-GAAP
financial measures, have been prepared in direct response to
questions from its investors and other interested parties. Although
the Company has frequently discussed these reconciling items when
they occur, both in its filings as well as in investment community
conference calls that are open to the public at large, many
inquiries are still made as to the nature of these items, and the
impact of removing these items from the GAAP financial results. As
a result, the Company believes it is important to provide these
reconciliations, so that the requesting investors will not have to
perform the arithmetic themselves and so that all interested
parties will benefit from the disclosures and reconciliations,
through a straightforward and unambiguous presentation. The Company
believes that the use and presentation of the terms EBITDA,
Adjusted Non-GAAP EBITDA and the other Non-GAAP financial measures
is useful because it allows readers of its financial information to
evaluate its performance for different periods on a more comparable
basis by excluding items that are unique in nature such as non-cash
compensation, or do not relate to the ongoing operation of its core
business. The items presented in calculating Adjusted Non-GAAP
EBITDA and other Non-GAAP reconciliations represent specific events
or items as follows (please see Exhibits 4 and 5 to this press
release): Cash Severance � costs associated with restructuring and
downsizing of the Company�s employee base during the three-month
periods ended March 31, 2008, and in connection with the sale of
the Company�s Australian-based lab and radiology assets in April
2008 (see Loss on Sale of Assets); Loss on Sale of Assets � a
one-time loss for accounting purposes recorded in connection with
the Company�s April 2008 sale of its Australia-based lab and
radiology business, with operations in Australia, New Zealand and
the United Kingdom; Non-Cash Compensation � the costs of employee
stock options and restricted stock; Tax Benefit, Net � the amount
recorded during the three months ended December 31, 2007 resulting
from the release of a portion of the reserve against the Company�s
deferred tax assets, net of deferred income tax expense recorded in
the period; Strategic Initiatives � the expenses recorded in
connection with merger and acquisition activities during the
three-month period ended June 30, 2007 and December 31, 2007;
Employment Matters � the cost of the Company�s review of wage/hour
classifications for certain employees during the three-month
periods ended December 31, 2007 and September 30, 2007. About
QuadraMed Corporation QuadraMed Corporation advances the success of
healthcare organizations through IT solutions that leverage quality
care into positive financial outcomes. QuadraMed provides real
world solutions that help healthcare professionals deliver
outstanding patient care efficiently and cost effectively. Behind
the Company�s products and services is a staff of 600 professionals
whose experience and dedication have earned QuadraMed the trust and
loyalty of clients at over 2,000 healthcare provider facilities.
For more information about QuadraMed, visit
http://www.quadramed.com. Cautionary Statement on Risks Associated
with QuadraMed Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 by QuadraMed that
are subject to risks and uncertainties. The words "believe,"
"expect," "anticipate," "intend," "plan," "estimate," "may,"
"should," "could," and similar expressions are intended to identify
such statements. Forward-looking statements are not guarantees of
future performance and are to be interpreted only as of the date on
which they are made. QuadraMed undertakes no obligation to update
or revise any forward-looking statement except as required by law.
QuadraMed advises investors that it discusses risk factors and
uncertainties that could cause QuadraMed�s actual results to differ
from forward-looking statements in its periodic reports filed with
the Securities and Exchange Commission ("SEC"). QuadraMed�s SEC
filings can be accessed through the Investor Relations section of
our website, www.quadramed.com, or through the SEC�s EDGAR Database
at www.sec.gov (QuadraMed has EDGAR CIK No. 0001018833). QuadraMed
Affinity and Care-based Revenue Cycle are registered trademarks of
QuadraMed Corporation. QuadraMed Corporation�s trademark: �Quality
Care. Financial Health� is pending registration. All other
trademarks are the property of their respective holders. � Exhibit
1 QUADRAMED CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in
thousands, except per share amounts) (unaudited) � June 30,
December 31, ASSETS 2008 2007 � Current assets Cash and cash
equivalents $ 14,603 $ 7,119 Short-term investments 3,892 9,169
Accounts receivable, net of allowance for doubtful accounts of
$1,393 and $1,449, respectively 23,985 26,088 Unbilled receivables
5,674 5,183 Deferred contract expenses 5,723 6,060 Prepaid expenses
and other current assets, net of allowance of $919 and $1,229,
respectively 8,029 5,367 Deferred tax asset, net of valuation
allowance � 7,377 � � 7,376 � Total current assets 69,283 66,362 �
Restricted cash 1,729 2,389 Long-term investments 4,659 1,197
Property and equipment, net of accumulated depreciation and
amortization of $22,951, and $22,855, respectively 3,464 3,778
Goodwill 34,346 33,942 Other amortizable intangible assets, net of
accumulated amortization of $28,522 and $31,119, respectively
10,355 11,768 Other long-term assets 3,212 3,182 Deferred tax
asset, net of valuation allowance � 49,740 � � 49,758 � Total
assets $ 176,788 � $ 172,376 � � LIABILITIES AND STOCKHOLDERS�
EQUITY Current liabilities Accounts payable and accrued expenses $
4,428 $ 4,910 Accrued payroll and related benefits 5,477 9,602
Accrued exit cost of facility closing 857 1,178 Other accrued
liabilities 5,244 7,537 Dividends payable 1,375 1,375 Deferred
revenue � 50,920 � � 36,111 � Total current liabilities 68,301
60,713 � Accrued exit cost of facility closing 451 888 Other
long-term liabilities � 2,195 � � 2,722 � Total liabilities 70,947
64,323 � Commitments and Contingencies � Stockholders� equity
Preferred stock, $0.01 par, 5,000 shares authorized, 4,000 shares
issued and outstanding, respectively 96,144 96,144 Common stock,
$0.01 par, 30,000 shares authorized; 9,406 and 9,178 shares issued
and 8,909 and 9,057 outstanding, respectively 98 459 Shares held in
treasury, 497 and 121, respectively (4,020 ) (292 ) Additional
paid-in-capital 312,898 310,557 Accumulated other comprehensive
gain (loss) 104 (80 ) Accumulated deficit � (299,383 ) � (298,735 )
Total stockholders� equity � 105,841 � � 108,053 � Total
liabilities and stockholders� equity $ 176,788 � $ 172,376 � � � �
� Exhibit 2 QUADRAMED CORPORATION CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS (in thousands, except per share amounts) (unaudited)
� Three months ended, Six months ended, June 30, June 30, 2008 2007
2008 2007 Revenue Services $ 5,605 $ 5,011 $ 11,172 $ 8,539
Maintenance 16,673 14,234 33,529 28,159 Installation and other �
3,132 � � 2,684 � � 6,461 � � 5,242 � Services and other revenue
25,410 21,929 51,162 41,940 � Term licenses 7,785 7,211 15,552
13,608 Perpetual licenses � 4,502 � � 2,304 � � 6,133 � � 4,581 �
Licenses 12,287 9,515 21,685 18,189 Hardware � 289 � � 2,918 � �
430 � � 3,439 � Total revenue � 37,986 � � 34,362 � � 73,277 � �
63,568 � � Cost of revenue Cost of services and other revenue
11,503 8,685 22,837 15,712 Royalties and other 3,877 4,057 7,694
7,036 Amortization of acquired technology and capitalized software
� 252 � � 354 � � 511 � � 825 � Cost of license revenue 4,129 4,411
8,205 7,861 Cost of hardware revenue � 128 � � 2,895 � � 264 � �
3,387 � Total cost of revenue � 15,760 � � 15,991 � � 31,306 � �
26,960 � Gross margin � 22,226 � � 18,371 � � 41,971 � � 36,608 � �
Operating expense General and administration 4,766 4,579 9,880
8,452 Software development 8,541 7,662 17,034 15,074 Sales and
marketing 4,177 3,913 9,137 7,809 Loss on sale of assets 1,115 -
1,115 - Amortization of intangible assets and depreciation � 812 �
� 875 � � 1,639 � � 1,798 � Total operating expenses � 19,411 � �
17,029 � � 38,805 � � 33,133 � Income from operations � 2,815 � �
1,342 � � 3,166 � � 3,475 � � Other income (expense) Interest
expense, includes non-cash charges of $20, $33 and $36, $84 (42 )
(33 ) (73 ) (83 ) Interest income 158 644 324 1,217 Other income,
net � 7 � � 409 � � 8 � � 486 � Other income, net � 123 � � 1,020 �
� 259 � � 1,620 � � Income from operations before income taxes $
2,938 $ 2,362 $ 3,425 $ 5,095 Provision for income taxes � (1,151 )
� (162 ) � (1,329 ) � (271 ) Net Income 1,787 2,200 2,096 4,824
Preferred stock accretion, dividend premium, and dividends declared
� (1,375 ) � (1,325 ) � (2,750 ) � (2,633 ) � Net income (loss)
attributable to common shareholders $ 412 � $ 875 � $ (654 ) $
2,191 � � Income (loss) per share Basic $ 0.05 $ 0.10 $ (0.07 ) $
0.25 Diluted $ 0.04 $ 0.09 $ (0.07 ) $ 0.23 � Weighted average
shares outstanding Basic 8,790 8,733 8,928 8,747 Diluted 9,460
9,453 8,928 9,464 � Exhibit 3 QUADRAMED CORPORATION CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) �
� Three months ended � Six months ended June 30, June 30, 2008 �
2007 2008 � 2007 Cash flows from operating activities Net income $
1,787 $ 2,200 $ 2,096 $ 4,824 Adjustments to reconcile net income
to net cash provided by operating activities: Depreciation and
amortization 1,065 1,230 2,151 2,624 Deferred compensation
amortization 94 96 188 192 Stock-based compensation 841 356 1,640
739 Provision for bad debts - 25 130 181 Loss on sale of assets
1,115 - 1,115 - Other (9 ) (10 ) (4 ) 5 � Changes in operating
assets and liabilities: Accounts receivable 6,620 2,797 (177 )
3,148 Prepaid expenses and other receivables 2,017 3,465 (2,364 )
3,173 Accounts payable and accrued liabilities (57 ) 82 (8,054 )
(4,586 ) Deferred revenue � (9,376 ) � (5,350 ) � 15,387 � � 3,474
� Cash provided by operating activities 4,097 4,891 12,108 13,774 �
Cash flows from investing activities Decrease in restricted cash
218 (148 ) 660 (94 ) Purchases of available-for-sale securities
(3,209 ) (16,107 ) (4,031 ) (33,466 ) Proceeds from sale of
available-for-sale securities 895 15,624 5,860 20,645 Payment of
acquisition costs 22 - (46 ) - Purchases of property and equipment
(753 ) (313 ) (844 ) (540 ) Proceeds from sale of assets � 106 � �
- � � 106 � � - � Cash (used in) provided by investing activities
(2,721 ) (944 ) 1,705 (13,455 ) � Cash flows from financing
activities Payment of preferred stock dividends (1,375 ) (1,375 )
(2,750 ) (2,878 ) Proceeds from issuance of common stock and other
24 401 149 1,435 Repurchase of common stock � (1,218 ) � - � �
(3,728 ) � - � Cash used in financing activities (2,569 ) (974 )
(6,329 ) (1,443 ) � Net (decrease) increase in cash and cash
equivalents (1,193 ) 2,973 7,484 (1,124 ) � Cash and cash
equivalents, beginning of period � 15,796 � � 28,499 � � 7,119 � �
32,596 � � Cash and cash equivalents, end of period $ 14,603 � $
31,472 � $ 14,603 � $ 31,472 � � Exhibit 4 QUADRAMED CORPORATION
RECONCILIATION OF EBITDA AND NON-GAAP MEASUREMENTS (in thousands)
(unaudited) � � � � � � � � � � For the Three Month Periods Ended
6/30/08 3/31/08 12/31/07 9/30/07 6/30/07 3/31/07 12/31/06 9/30/06 �
EBITDA (Earnings Before Interest, Taxes, Depreciation and
Amortization) � Net income, as reported $ 1,787 $ 309 $ 56,674 $
1,502 $ 2,200 $ 2,624 $ 3,962 $ 5,979 � � Adjustments to Net Income
for EBITDA Interest Expense 42 31 20 24 33 50 68 85 � Interest
Income (158 ) (166 ) (364 ) (699 ) (644 ) (573 ) (480 ) (501 )
(Provision) benefit for Income Taxes 1,151 178 (52,821 ) 142 162
109 80 101 � Depreciation and Amortization � 1,159 � � 1,180 � �
1,323 � � 802 � � 1,326 � � 1,490 � � 1,757 � � 1,878 � Subtotal
Non-GAAP Adjustments for EBITDA 2,194 1,223 (51,842 ) 269 877 1,076
1,425 1,563 � � � � � � � � � EBITDA $ 3,981 � $ 1,532 � $ 4,832 �
$ 1,771 � $ 3,077 � $ 3,700 � $ 5,387 � $ 7,542 � EBITDA % to
Revenue 10.5 % 4.3 % 11.8 % 5.4 % 9.0 % 12.7 % 17.3 % 22.8 % �
Non-GAAP Adjustments to EBITDA Non-cash Compensation 842 799 928
807 356 383 182 229 � Cash Severance 161 561 - - - - - - � Loss on
Sale of Assets � 1,115 � � - � � - � � - � � - � � - � � - � � - �
Subtotal Non-GAAP Adjustments to EBITDA 2,118 1,360 928 807 356 383
182 229 � � � � � � � � � Adjusted Non-GAAP EBITDA $ 6,099 � $
2,892 � $ 5,760 � $ 2,578 � $ 3,433 � $ 4,083 � $ 5,569 � $ 7,771 �
Adjusted Non-GAAP EBITDA % to Revenue 16.1 % 8.2 % 14.1 % 7.8 %
10.0 % 14.0 % 17.8 % 23.5 % � � Non-GAAP Net Income before
Preferred Stock Accretion � Net income, as reported $ 1,787 $ 309 $
56,674 $ 1,502 $ 2,200 $ 2,624 $ 3,962 $ 5,979 � � Non-GAAP
adjustments to Net income Non-cash Compensation 842 799 928 807 356
383 182 229 � Cash Severance 161 561 - - - - - - � Strategic
Initiatives - - 57 - 412 - - - � Tax benefit, Net - - (52,898 ) - -
- - - � Employment Matters - - (374 ) 1,544 - - - - � Loss on Sale
of Assets � 1,115 � � - � � - � � - � � - � � - � � - � � - �
Subtotal Non-GAAP adjustments 2,118 1,360 (52,287 ) 2,351 768 383
182 229 � � � � � � � � � Non-GAAP Net income $ 3,905 � $ 1,669 � $
4,387 � $ 3,853 � $ 2,968 � $ 3,007 � $ 4,144 � $ 6,208 � � Other
Information � Revenue $ 37,986 $ 35,291 $ 40,874 $ 32,908 $ 34,362
$ 29,206 $ 31,213 $ 33,032 � Costs of Revenue $ 15,760 � $ 15,546 �
$ 16,167 � $ 14,105 � $ 15,991 � $ 10,969 � $ 11,401 � $ 10,436 �
Gross Margin $ 22,226 � $ 19,745 � $ 24,707 � $ 18,803 � $ 18,371 �
$ 18,237 � $ 19,812 � $ 22,596 � Gross Margin % 59 % 56 % 60 % 57 %
53 % 62 % 63 % 68 % About Adjusted Non-GAAP EBITDA and other
Non-GAAP Measurements The Company�s use and presentation of the
terms EBITDA, Adjusted Non-GAAP EBITDA and other Non-GAAP
Measurements included in this press release and Exhibits 4 and 5
thereto, and the reconciliations of those items to the most
directly comparable GAAP financial measure with equal or greater
prominence as the Non-GAAP financial measures, have been prepared
in direct response to questions from its investors and other
interested parties. Although the Company has frequently discussed
these reconciling items when they occur, both in its filings as
well as in investment community conference calls that are open to
the public at large, many inquiries are still made as to the nature
of these items, and the impact of removing these items from the
GAAP financial results. As a result, the Company believes it is
important to provide these reconciliations, so that the requesting
investors will not have to perform the arithmetic themselves and so
that all interested parties will benefit from the disclosures and
reconciliations, through a straightforward and unambiguous
presentation. The Company believes that the use and presentation of
the terms EBITDA, Adjusted Non-GAAP EBITDA and the other Non-GAAP
financial measures is useful because it allows readers of its
financial information to evaluate its performance for different
periods on a more comparable basis by excluding items that are
unique in nature such as non-cash compensation, or do not relate to
the ongoing operation of its core business. The items presented in
calculating Adjusted Non-GAAP EBITDA and other Non-GAAP
reconciliations represent specific events or items as follows
(please see Exhibits 4 and 5 to this press release): Cash Severance
-- costs associated with restructuring and downsizing of the
Company�s employee base during the three-month periods ended March
31, 2008, and in connection with the sale of the Company�s lab and
radiology assets in April 2008 (see Loss on Sale of Assets); Loss
on Sale of Assets � a one-time loss for accounting purposes
recorded in connection with the Company�s April 2008 sale of its
Australia-based lab and radiology business, with operations in
Australia, New Zealand and the United Kingdom; Non-cash
Compensation � the costs of employee stock options and restricted
stock; Tax benefit, Net � the amount recorded during the three
months ended December 31, 2007 resulting from the release of a
portion of the reserve against the Company�s deferred tax assets,
net of deferred income tax expense recorded in the period;
Strategic Initiatives � the expenses recorded in connection with
merger and acquisition activities during the three-month period
ended June 30, 2007 and December 31, 2007; Employment Matters � the
cost of the Company�s review of wage/hour classifications for
certain employees during the three-month periods ended December 31,
2007 and September 30, 2007. � Exhibit 5 QUADRAMED CORPORATION
Reconciliation of EBITDA and Non-GAAP Measurements (in thousands)
(unaudited) � � For the Six Months Ended 6/30/2008 6/30/2007 � �
EBITDA (Earnings Before Interest, Taxes, Depreciation and
Amortization) � Net income, as reported $ 2,096 $ 4,824 �
Adjustments to Net Income for EBITDA Interest Expense 73 83
Interest Income (324 ) (1,217 ) Provision for Income Taxes 1,329
271 Depreciation and Amortization � 2,339 � � 2,816 � Subtotal
Non-GAAP Adjustments for EBITDA 3,417 1,953 � � EBITDA $ 5,513 � $
6,777 � EBITDA % to Revenue 7.5 % 10.7 % � Non-GAAP Adjustments to
EBITDA Non-cash Compensation 1,641 739 Cash Severance 722 - Loss on
Sale of Assets � 1,115 � � - � Subtotal Non-GAAP Adjustments to
EBITDA 3,478 739 � � Adjusted Non-GAAP EBITDA $ 8,991 � $ 7,516 �
Adjusted Non-GAAP EBITDA % to Revenue 12.3 % 11.8 % � � Non-GAAP
Net Income before Preferred Stock Accretion � Net income, as
reported $ 2,096 $ 4,824 � Non-GAAP adjustments to Net income
Non-cash Compensation 1,641 739 Cash Severance 722 - Strategic
Initiatives - 412 Loss on Sale of Assets � 1,115 � � - � Subtotal
Non-GAAP adjustments 3,478 1,151 � � Non-GAAP net income $ 5,574 �
$ 5,975 � � Other Information � Revenue $ 73,277 $ 63,568 Costs of
Revenue $ 31,306 � $ 26,960 � Gross Margin $ 41,971 � $ 36,608 �
Gross Margin % 57 % 58 % About Adjusted Non-GAAP EBITDA and other
Non-GAAP Measurements The Company�s use and presentation of the
terms EBITDA, Adjusted Non-GAAP EBITDA and other Non-GAAP
Measurements included in this press release and on this Exhibits 4
and 5 thereto, and the reconciliations of those items to the most
directly comparable GAAP financial measure with equal or greater
prominence as the Non-GAAP financial measures, have been prepared
in direct response to questions from its investors and other
interested parties. Although the Company has frequently discussed
these reconciling items when they occur, both in its filings as
well as in investment community conference calls that are open to
the public at large, many inquiries are still made as to the nature
of these items, and the impact of removing these items from the
GAAP financial results. As a result, the Company believes it is
important to provide these reconciliations, so that the requesting
investors will not have to perform the arithmetic themselves and so
that all interested parties will benefit from the disclosures and
reconciliations, through a straightforward and unambiguous
presentation. The Company believes that the use and presentation of
the terms EBITDA, Adjusted Non-GAAP EBITDA and the other Non-GAAP
financial measures is useful because it allows readers of its
financial information to evaluate its performance for different
periods on a more comparable basis by excluding items that are
unique in nature such as non-cash compensation, or do not relate to
the ongoing operation of its core business. The items presented in
calculating Adjusted Non-GAAP EBITDA and other Non-GAAP
reconciliations represent specific events or items as follows: Cash
Severance -- costs associated with restructuring and downsizing of
the Company�s employee base during the three-month periods ended
March 31, 2008, and in connection with the sale of the Company�s
lab and radiology assets in April 2008 (see Loss on Sale of
Assets); Loss on Sale of Assets � a one-time loss for accounting
purposes recorded in connection with the Company�s April 2008 sale
of its Australia-based lab and radiology business with operations
in Australia, New Zealand and the United Kingdom; Non-cash
Compensation � the costs of employee stock options and restricted
stock; Tax benefit, Net � the amount recorded during the three
months ended December 31, 2007 resulting from the release of a
portion of the reserve against the Company�s deferred tax assets,
net of deferred income tax expense recorded in the period;
Strategic Initiatives � the expenses recorded in connection with
merger and acquisition activities during the three-month period
ended June 30, 2007 and December 31, 2007; Employment Matters � the
cost of the Company�s review of wage/hour classifications for
certain employees during the three-month periods ended December 31,
2007 and September 30, 2007.
Quadramed Corp (MM) (NASDAQ:QDHC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Quadramed Corp (MM) (NASDAQ:QDHC)
Historical Stock Chart
From Jul 2023 to Jul 2024